Welcome to the Wnt & β-Catenin Targeted Drug Discovery Summit
Returning for its for 2nd edition, the Wnt/B-Catenin Targeted Drug Development Summit will host the leaders from Academia, Pharma and Biotech’s, to focus on driving translational research and drug development for Wnt/β-Catenin Candidates.
After 2 decades of research, it is now the time for drug developers to act and get together at the 2nd Wnt/β-Catenin Pathway Targeted Drug Development Summit. As the one and only industry-led meeting, you hear all the latest insights in topics from looking at structural biology and modulation approaches, through to validating clinical biomarkers and reducing toxicity.
If you’re working in the Wnt/B-Catenin or IO space, or want to learn more about its potential for drug development, this is your chance to ask questions to the experts in the field, network with 80+ industry players, and gain invaluable insights to take you in 2023 and beyond.
What you will learn:
The best therapeutic strategies for targeting the Wnt/B-Catenin Pathway
Intracellular methods for targeting Wnt downstream
Different inhibitor approaches to block Wnt/B-Catenin Signalling
Looking at improving our immune-oncology understanding of Wnt Pathways and Immune Cells
How to overcome or preempt safety and scheduling challenges
Learning the newest clinical updates from the industry
Who you will meet:
Academics
Bio-Techs
Pharmaceutical Companies
2021's Expert Speakers Included
Rami N. Hannoush
Senior Principal Scientist and Group Leader, Early Discovery Biochemistry
Genentech
